Xeris Biopharma Holdings, Inc. (XERS)
After hours:
| Previous close | 1.7500 |
| Open | 1.7900 |
| Bid | 1.8400 x 400 |
| Ask | 1.8700 x 800 |
| Day's range | 1.7500 - 1.8800 |
| 52-week range | 1.4600 - 3.2600 |
| Volume | |
| Avg. volume | 1,884,547 |
| Market cap | 275.752M |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4500 |
| Earnings date | 06 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.75 |
Simply Wall St.Pleasing Signs As A Number Of Insiders Buy Xeris Biopharma Holdings Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Business WireXeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
CHICAGO, May 02, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2024 financial results before the open of the U.S. financial markets on Thursday, May 9, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Comp
ZacksStrength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
